Replies to post #93928 on Avid Bioservices Inc (CDMO)

[drragmop]

"In May 2011, the Food and Drug Administration (FDA) approved the drug telaprevir (Incivek), an oral treatment for hepatitis C marketed by Vertex."

"January 31, 2012, Vertex gained FDA approval[4] of the first drug, ivacaftor,[5] to treat the underlying cause of cystic fibrosis rather than the symptoms, in patients over age 6 who have the G551D gene mutation. In the US, 30,000 people have cystic fibrosis. About 4% of those, or 1,200, have the G551D gene mutation. Vertex is marketing the drug at $294,000 a year per patient."

From Wikipedia.

I think I've made enough valuation posts.